Health News Releases

  • Today May 18
December 18, 2018 18:20
Fuji Pharma Invests in Alvotech for US$50 Million
Biopharmaceutical company Alvotech announced today that Japan-based Fuji Pharma has acquired a 4.2% stake in the business for approximately US$50 million. Alvotech and Fuji Pharma recently announce
December 18, 2018 14:25
Brightree Acquires Mobile Delivery Provider Apacheta to Streamline HME Delivery
Brightree, a leading provider of cloud-based software helping out-of-hospital providers improve business performance and patient outcomes, today announced it has acquired privately held mobile deliver
December 18, 2018 11:10
Celgene Corporation Announces Celgene Cancer Care Links™ Program Grant Recipients
Celgene Corporation (NASDAQ:CELG) today announced ten programs selected for funding under its Celgene Cancer Care Links™ program, an initiative designed to support cancer healthcare capacity building
December 17, 2018 16:00
Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the ex
December 17, 2018 09:25
Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer
Boehringer Ingelheim announced today the first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and safety of Vargatef® (
December 13, 2018 16:10
Takeda and the New York Academy of Sciences Announce 2019 Innovators in Science Award Winners
Takeda Pharmaceutical Company Limited, (“Takeda”) (TSE:4502) and the New York Academy of Sciences announced today the Winners of the second annual Innovators in Science Award for their commitment to a
December 12, 2018 10:15
AMRA Receives U.S. FDA Clearance for AMRA® Profiler, a Magnetic Resonance Diagnostic Software Application Enabling Non-Invasive Evaluation of Body Composition
AMRA Medical (“AMRA”), the international leader in body composition analysis, announced today that it has received FDA clearance for AMRA® Profiler, now available for use in a clinical setting in the
December 10, 2018 10:05
Vitruvias Therapeutics Inc., Licenses Potassium Chloride ER ANDA (10 and 20 mEq) Capsules to Be Manufactured at Bora Pharmaceutical’s New Zhunan Facility in Taiwan
Vitruvias Therapeutics Inc., an Auburn, Alabama-based finished-dose generic drug development company, has agreed to license an approved Potassium Chloride Extended release ANDA. The product will be ma
December 06, 2018 13:40
Takeda Shareholders Approve Resolutions Related to the Proposed Acquisition of Shire plc
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
December 05, 2018 17:50
Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas
Seattle Genetics, Inc. (Nasdaq:SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) announced that data from the ECHELON-2 phase 3 clinical trial will be presented today in an oral session at th
December 05, 2018 13:45
Takeda Announces Execution of Loan Agreement in Connection with Proposed Acquisition of Shire plc
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
December 04, 2018 17:55
ResMed to Acquire Propeller Health, a Leader in COPD and Asthma Connected Health Solutions, for $225 Million
ResMed (NYSE: RMD) (ASX: RMD), a leader in cloud-connected medical devices and out-of-hospital software-as-a-service (SaaS) business solutions, today announced it has entered a definitive agreement to
December 04, 2018 11:55
Tiziana Completes Patient Enrollment in a Phase 2a Trial to Evaluate Tolerability and Anti-Tumor Activity of Milciclib in Hepatocellular Carcinoma (HCC)
Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces
December 04, 2018 11:40
Takeda to Present Positive Data from TOURMALINE-MM3, First Pivotal Phase 3 Placebo Controlled Trial Evaluating Proteasome Inhibitor Treatment in Maintenance Setting
Takeda Pharmaceutical Company Limited (TSE:4502) today announced that data from the Phase 3 randomized, TOURMALINE-MM3 study evaluating the effect of single-agent oral NINLARO™ (ixazomib) as a mainten
December 04, 2018 10:35
Celgene Corporation Announces Initial Clinical Data from Ongoing Phase 1/2 Evolve Trial with Anti-BCMA CAR T Therapy JCARH125 in Relapsed/Refractory Multiple Myeloma at ASH 2018
Celgene Corporation (NASDAQ:CELG) today announced initial safety data from its ongoing proof-of-concept trial of JCARH125 in patients with relapsed/refractory multiple myeloma. JCARH125 is an investig
December 04, 2018 09:05
Alteogen and Lynkogen Expand Agreement to Include Additional Proprietary Fusion Proteins Targeting NASH
Alteogen Inc. (196170.KQ) and Lynkogen Inc. today announced that they have expanded the scope of their exclusive option agreement. In addition to the originally announced GLP-1 mimetic fusion proteins
December 03, 2018 20:00
Vitruvias Therapeutics Inc., and Sunny Pharmtech Inc., Announce the FDA Approval of Generic Aminocaproic Acid 500 mg and 1000 mg Tablets
Sunny Pharmtech, Inc., a Taiwan-based API and finished-dose drug development company, and Vitruvius Therapeutics Inc., an Auburn, Alabama-based generic drug company announced today that their Abbrevia
December 03, 2018 19:35
ACM Global Laboratories Appoints Brian Wright as President
Rochester Regional Health (RRH), a $2.2 USD billion integrated health care delivery system with more than 17,000 employees, has announced that its wholly-owned subsidiary, ACM Global Laboratories, has
December 03, 2018 15:45
European Commission Approves ALUNBRIG® (brigatinib) for ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib, Advancing Treatment Paradigm in Europe
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Commission (EC) granted marketing authorization for ALUNBRIG (brigatinib) as a monotherapy for the treatment of adul
December 03, 2018 14:25
Celgene Corporation Announces Results of AUGMENT Evaluating REVLIMID® In Combination with Rituximab (R2) In Patients with Relapsed/Refractory Indolent Lymphoma At ASH 2018
Celgene Corporation (NASDAQ: CELG) today announced results of the phase 3 AUGMENT study, which showed that REVLIMID® (lenalidomide) in combination with rituximab (R2) demonstrated superior progression
December 03, 2018 13:55
Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 MEDALIST Trial Evaluating Luspatercept in Patients with Myelodysplastic Syndromes at the ASH 2018 Plenary Session
Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced results from the pivotal, phase 3 MEDALIST trial evaluating the efficacy and safety of investigational luspa
December 03, 2018 13:05
Celgene Corporation Announces Initial Phase 1/2 Liso-cel Data in Patients with Relapsed/Refractory CLL, Including Those with High-Risk Disease, Previously Treated with Ibrutinib, at ASH 2018
Celgene Corporation (NASDAQ: CELG) today announced initial data from the dose-escalation part of an ongoing, open-label multicenter phase 1/2 study of investigational lisocabtagene maraleucel (liso-ce
December 03, 2018 11:55
Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 BELIEVE Trial Evaluating Luspatercept in Adult Patients with Beta-Thalassemia at ASH 2018
Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced results from a pivotal, phase 3 trial (BELIEVE) evaluating the safety and efficacy of luspatercept for the t
November 30, 2018 18:00
FDA Clears SpinalCyte IND Application for Universal Donor Cell Therapy to Treat Lower Back Pain
SpinalCyte, LLC, a Texas-based regenerative medicine company focused on regrowth of the spinal disc nucleus using its universal donor product, CybroCell™, today announced the FDA has cleared its Inves
November 28, 2018 13:05
American College of Cardiology recommends empagliflozin as preferred SGLT2 inhibitor for adults with type 2 diabetes and established cardiovascular disease in new Expert Consensus Decision Pathway
A new Expert Consensus Decision Pathway issued by the American College of Cardiology (ACC) recommends empagliflozin as the preferred SGLT2 inhibitor for its proven benefit in reducing the risk of card
25 per page50 per page75 per page100 per page